Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

compounds.
  • On April 21, InterMune reported that the INFORM-1 study had been expanded by three additional cohorts to explore the interferon-free regimen in treatment-experienced patients, both treatment failures and null-responder HCV patients, and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient cohorts.
  • Today the company announced that results of all seven cohorts of INFORM-1 will be presented in Presidential Plenary Session III (#193) at the 2009 AASLD meeting at 8:00 a.m. on November 3. The company also announced today that two additional abstracts on the topics of the PK/PD profile (#1594) and the viral resistance profile (#1585) of the INFORM-1 regimen have been accepted for poster presentations at the 2009 AASLD meeting, also on November 3.
  • 2009 Key Project Guidance

    The company provided the following guidance on its key development projects, pirfenidone and ITMN-191.

        Milestones And Key Events                              Expected Date
        -------------------------                              -------------
        Pirfenidone
        -----------
        Oral presentation on pirfenidone at ERS              September 14, 2009
        ---------------------------------------              ------------------
        Submission of pirfenidone NDA to FDA                            Q4 2009
        ------------------------------------                            -------
        Submission of pirfenidone MAA to EMEA                           Q1 2010
        -------------------------------------                           -------
    
        ITMN-191 (R7227)
        ---------------
        Phase 2b initiation by Roche ($20 million payment
         to InterMune)                                              August 2009
        -------------------------------------------------       
    '/>"/>
    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. InterMune to Release Second Quarter Financial Results on August 6
    2. InterMune to Present at Goldman Sachs Healthcare Conference
    3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
    4. InterMune to Release First Quarter Financial Results on April 30
    5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    6. InterMune to Present at Canaccord Adams Hepatitis C Conference
    7. InterMune to Present at Citis 4th Annual Biotech Day
    8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
    (Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
    (Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
    (Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
    Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
    ... , SUNNYVALE, Calif., Oct. 13 Cepheid (Nasdaq: CPHD ... its third quarter ended September 30, 2009, on Wednesday, October ... company will host a management presentation at 2 p.m. Pacific ... To access the live webcast, please visit Cepheid,s website ...
    ... Novavax, Inc. (Nasdaq: NVAX ) announced today that it ... from the National Institute of Allergy and Infectious Diseases (NIAID) ... from the NIAID is to support a segment of the ... particle-based vaccine. RSV is the most commonly identified cause ...
    ... CAMBRIDGE, Mass., Oct. 13 Cequent Pharmaceuticals, a pioneer ... treatments to prevent and treat human disease, announced that ... Cequent,s planned launch of its clinical program and highlight ... for 3 p.m. on Tuesday, October 27, 2009, at ...
    Cached Biology Technology:Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 3Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27 2
    (Date:9/2/2014)... September 2, 2014 Best-selling author Sam Kean stops ... the Megalodon, the 50-foot super shark that, despite what ... extinct. Learn all about it at http://youtu.be/KhFygIoW_MA . ... Tales of Madness, Love and the History of the ... getting the Reactions treatment in a 10-episode video series ...
    (Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
    (Date:9/1/2014)... the U.S. undergoes a battery of tests designed to ... Thousands of children born in the developing world, however, ... the disease each year. , A.J. Kumar hopes ... those deaths. , A Post-Doctoral Fellow in Chemistry ... Whitesides, the Woodford L. and Ann A. Flowers University ...
    Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
    ... school students and teachers sounds like a witches brew for an ... Instead, these are the components that comprise the ... developed by researchers at Washington University in St. Louis and a ... Lars Angenent, Ph.D., assistant professor of ...
    ... a pair of proteins that work in concert to restart ... dormancy. The Hawley Lab has described the dual ... that awakens the long-dormant egg, allowing for production of a ... Dec. 4, 2007 issue of PLoS Biology. The ...
    ... may have begun in the protected spaces inside of layers ... new hypothesis. The hypothesis was developed by Helen Hansma, ... and a program director at the National Science Foundation. Hansma ... Dec. 4, at the annual meeting of the American Society ...
    Cached Biology News:Microbial fuel cells turn on the juice 2Microbial fuel cells turn on the juice 3Stowers Institute's Hawley Lab identifies factors responsible for restart of meiotic cycle 2New hypothesis for origin of life proposed 2
    ... Blot Processing Standard Tray (3 ... for gel staining and blot processing.Automated ... gels for proteins and nucleic acid ... detection and chromogenic detection.Programmable control of ...
    ... Dithiothreitol, 1 g. High quality ... sample preparation that give consistent ... cells and tissues.Clean up samples ... volumes. Accurately quantitate protein for ...
    IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
    ANTI MYCOBACTERIUM TUBERCULOSIS...
    Biology Products: